Get the Stockscreener App
0.1805
11.95%
-0.0245
After Hours:
.18
-0.0005
-0.28%
Theriva Biologics Inc stock is traded at $0.1805, with a volume of 2.35M.
It is down -11.95% in the last 24 hours and down -17.20% over the past month.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11. It has collaborations with The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
See More
Previous Close:
$0.205
Open:
$0.1943
24h Volume:
2.35M
Relative Volume:
0.48
Market Cap:
$6.44M
Revenue:
-
Net Income/Loss:
$-18.35M
P/E Ratio:
-0.1556
EPS:
-1.16
Net Cash Flow:
$-19.20M
1W Performance:
-9.70%
1M Performance:
-17.20%
6M Performance:
-57.99%
1Y Performance:
-88.20%
1-Day Range:
$0.1805
$0.1953
1-Week Range:
$0.1805
$0.22
52-Week Range:
$0.1651
$1.75
Theriva Biologics Inc Stock (TOVX) Company Profile
Name
Theriva Biologics Inc
Sector
Industry
Phone
301 417 4364
Address
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.1805 | 7.32M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Theriva Biologics Inc Stock (TOVX) Latest News
Theriva Biologics Faces Delay in Warrant Approval Meeting - TipRanks
Theriva Biologics Reschedules Stockholder Meeting - TradingView
Theriva Biologics (NYSE: TOVX) to reschedule vote on 16.18M warrant shares - Stock Titan
Death Cross: Can Theriva Biologics Inc. grow without dilutionJuly 2025 Selloffs & Daily Entry Point Trade Alerts - mfd.ru
Analyst Downgrade: Why is Theriva Biologics Inc stock going downJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Bond Watch: Is Theriva Biologics Inc. subject to activist investor interest2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Trial tests VCN-01 before eye removal in hard-to-treat retinoblastoma - Stock Titan
Street Watch: Is Theriva Biologics Inc showing insider buyingWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Theriva Biologics Inc backed by strong institutional buyingJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell? - Defense World
Dow Update: Can Theriva Biologics Inc continue delivering strong returnsWeekly Trade Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Theriva Biologics Inc continue delivering strong returnsQuarterly Portfolio Summary & Long-Term Growth Plans - baoquankhu1.vn
Theriva Biologics advances VCN-01 toward Phase 3 trial - TipRanks
How Theriva Biologics Inc. stock performs in rate cut cyclesProfit Target & Consistent Growth Equity Picks - Улправда
How Theriva Biologics Inc. stock reacts to fiscal policiesPortfolio Return Summary & AI Forecasted Entry/Exit Points - Улправда
Will Theriva Biologics Inc. stock profit from fiscal stimulusJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - Улправда
Can Theriva Biologics Inc. stock maintain operating margins2025 Trading Recap & Technical Analysis for Trade Confirmation - Улправда
Is Theriva Biologics Inc. stock undervalued vs historical averagesOil Prices & Risk Managed Investment Entry Signals - Улправда
Can Theriva Biologics Inc. stock deliver sustainable ROE2025 Technical Overview & Comprehensive Market Scan Insights - ulpravda.ru
Will Theriva Biologics Inc. stock benefit from green energy trends2026 world cup usa national team semifinals defensive leaders pressing system match prediction preview - ulpravda.ru
Why Theriva Biologics Inc. stock is favored by pension funds2026 world cup usa national team quarterfinals goalkeepers low block defense match prediction statistical analysis - Улправда
How Theriva Biologics Inc. stock benefits from strong dollar2026 world cup usa national team group stage playmakers possession football winner prediction insights - Улправда
Theriva Biologics Incto Schedule End-of-Ph - 富途牛牛
Sentiment Watch: Is Theriva Biologics Inc stock at risk of policy regulationJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - Bộ Nội Vụ
Theriva Biologics receives EMA approval for VCN-01 Phase 3 trial - Intellectia AI
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design - Yahoo Finance
Theriva Biologics gains EMA backing for VCN-01 phase 3 - MSN
Theriva receives EMA guidance for pancreatic cancer drug trial design By Investing.com - Investing.com Nigeria
Why Is Theriva Biologics Stock Gaining Monday? - Benzinga
Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com Nigeria
Theriva Biologics (TOVX) Prepares for Phase 3 Trial with EMA Gui - GuruFocus
Theriva Biologics Announces EMA Advice on Phase 3 Trial for VCN-01 - TradingView — Track All Markets
Theriva Biologics (TOVX) outlines EMA CHMP advice on VCN-01 Phase 3 trial in metastatic pancreatic cancer - Stock Titan
Theriva™ Biologics Announces Positive Scientific Advice - GlobeNewswire
Guidance Update: What market sentiment indicators show for Theriva Biologics Inc. (SFY0) stock2025 Macro Impact & Growth Focused Entry Point Reports - Bộ Nội Vụ
Theriva Biologics (NYSEAMERICAN:TOVX) Trading 5.2% Higher – Here’s Why - Defense World
What drives Theriva Biologics Inc stock priceDebt-to-Equity Ratio Analysis & Free Expert Stock Watchlists - earlytimes.in
Theriva Biologics (TOVX) asks holders to OK 16.18M warrant shares, $8.7M cash - Stock Titan
Have you been able to find a good deal on Theriva Biologics Inc’s shares? - uspostnews.com
Highs Report: Why institutional investors increase stakes in Theriva Biologics Inc. (SFY0) stock2025 Market Sentiment & Safe Swing Trade Setup Alerts - moha.gov.vn
Why Theriva Biologics Inc. stock appeals to dividend investorsJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - Улправда
Hedge Fund Moves: Is Theriva Biologics Inc. stock supported by strong fundamentals2025 Market Overview & Precise Entry and Exit Recommendations - Улправда
Is Theriva Biologics Inc. stock supported by strong fundamentals - Улправда
How risky is Theriva Biologics Inc. stock nowFed Meeting & Free Accurate Trade Setup Notifications - Улправда
Can Theriva Biologics Inc. stock deliver strong Q4 earningsJuly 2025 Technicals & Daily Oversold Stock Bounce Ideas - DonanımHaber
Is Theriva Biologics Inc. stock at risk of policy regulationJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - DonanımHaber
What analyst consensus implies for Theriva Biologics Inc. (SFY0) stockJuly 2025 Catalysts & Short-Term Swing Trade Alerts - Улправда
Is Theriva Biologics Inc. stock a fit for income portfoliosJuly 2025 Fed Impact & High Return Stock Watch Alerts - DonanımHaber
Can Theriva Biologics Inc. stock sustain free cash flow growthWeekly Trade Review & Community Verified Swing Trade Signals - Улправда
Will Theriva Biologics Inc. (SFY0) stock draw ESG focused funds2025 Sector Review & Free Expert Approved Momentum Trade Ideas - Улправда
Why analysts recommend Theriva Biologics Inc. stock2025 EndofYear Setup & Fast Gain Stock Trading Tips - Улправда
Theriva Biologics Inc Stock (TOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Cap:
|
Volume (24h):